STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Quarterly ResultMay 6, 2026, 04:17 PM

Repligen Q1 Revenue $194.26M, Net Income $8.33M; Divests Polymem

AI Summary

Repligen reported a rise in Q1 2026 total revenue to $194.26 million, up from $169.17 million in the prior year. Net income also increased to $8.33 million, or $0.15 per basic share, compared to $5.83 million, or $0.10 per basic share, in Q1 2025. The company completed the sale of Polymem S.A.S. for approximately $4.4 million, resulting in a $13.8 million loss on sale, and initiated restructuring activities to optimize its global manufacturing footprint.

Key Highlights

  • Completed the sale of Polymem S.A.S. for approximately $4.4 million, recognizing a $13.8 million loss.
  • Q1 2026 total revenue increased to $194.26 million from $169.17 million in Q1 2025.
  • Q1 2026 net income rose to $8.33 million, up from $5.83 million in Q1 2025.
  • Basic EPS for Q1 2026 was $0.15, compared to $0.10 in Q1 2025.
  • Cash and cash equivalents were $582.65 million as of March 31, 2026.
  • Total assets were $2,930.77 million as of March 31, 2026.
  • Incurred $1.50 million in restructuring activities and other charges in Q1 2026.
  • Goodwill decreased to $1,106.87 million as of March 31, 2026.
RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
REPLIGEN CORP

Price Impact